10-Q: Co-Diagnostics Faces Going Concern Amid Revenue Plunge

Co-Diagnostics reported a significant revenue decline and increased operating cash burn, leading to a 'going concern' warning despite recent capital raises.

Summary

• Total revenue for the three months ended September 30, 2025, decreased to $0.1 million from $0.6 million in the prior year, primarily due to lower grant revenues.
• Total revenue for the nine months ended September 30, 2025, fell to $0.4 million from $3.8 million in the same period last year, driven by reduced product and grant revenues.
• Net loss for the three months ended September 30, 2025, was $5.9 million, an improvement from $9.7 million in the prior year, attributed to lower operating expenses and an income tax benefit.
• Net loss for the nine months ended September 30, 2025, was $21.2 million, compared to $26.6 million in the prior year, also benefiting from decreased operating expenses and an income tax benefit.
• Cash and cash equivalents increased to $11.4 million as of September 30, 2025, from $2.9 million at December 31, 2024, largely due to financing activities.
• Net cash used in operating activities increased to $22.9 million for the nine months ended September 30, 2025, from $20.9 million in the prior year.
• The company withdrew its 510(k) application for the Co-Dx PCR COVID-19 Test due to shelf-life stability concerns and plans to resubmit an enhanced version.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for the next 12 months.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a severe decline in revenue, increased operational cash burn, and a 'going concern' warning. While the company has reduced net losses and raised capital, these actions are primarily reactive to significant underlying business challenges and do not indicate a strong, sustainable turnaround. The FDA application withdrawal for a key product further dampens prospects.

Positives

• Net loss decreased to $5.9 million for Q3 2025 from $9.7 million for Q3 2024, and to $21.2 million for the nine months ended September 30, 2025, from $26.6 million for the same period in 2024, primarily due to reduced operating expenses and an income tax benefit.
• Operating expenses decreased significantly, with total operating expenses falling to $7.1 million for Q3 2025 from $10.6 million for Q3 2024, and to $23.9 million for the nine months ended September 30, 2025, from $31.2 million for the same period in 2024.
• Cash and cash equivalents increased substantially to $11.4 million as of September 30, 2025, from $2.9 million at December 31, 2024, bolstered by recent equity financings.
• An income tax benefit of $1.16 million for Q3 2025 and $1.14 million for the nine months ended September 30, 2025, was recognized due to new U.S. tax legislation, with expected refunds by year-end.
• The company entered into a new Equity Distribution Agreement with Maxim Group LLC for an at-the-market (ATM) equity offering program of up to $10.0 million, providing future financial flexibility.
• A new joint venture with Arabian Eagle Manufacturing was formed to research, develop, manufacture, and commercialize Co-Dx technologies in the Middle East and North Africa.

Negatives

• Total revenue plummeted to $0.1 million for Q3 2025 from $0.6 million for Q3 2024, and to $0.4 million for the nine months ended September 30, 2025, from $3.8 million for the same period in 2024, primarily due to a significant drop in grant revenue and product sales.
• Net cash used in operating activities increased to $22.9 million for the nine months ended September 30, 2025, compared to $20.9 million for the same period in 2024, indicating a higher cash burn from core operations.
• The company's total current assets decreased to $14.1 million at September 30, 2025, from $32.3 million at December 31, 2024.
• The 510(k) application for the Co-Dx PCR COVID-19 Test was withdrawn due to concerns regarding shelf-life stability, delaying commercialization of a key product.
• The company continues to incur significant losses, with an accumulated deficit of $54.2 million as of September 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, dependent on obtaining necessary financing and achieving profitable operations.
• The ability to obtain additional financing through equity capital markets is subject to market and economic conditions, company performance, and investor sentiment, with no assurance of acceptable terms or availability.
• There is no guarantee that the Co-Dx PCR platform will receive necessary regulatory approvals for commercialization, or that it can be successfully commercialized even if approved.
• Cash received from federal grants, contracts, and awards can be subject to audit by the grantor, and any disallowance of expenditures could require repayment.
• The company is a defendant in one class action claim and three derivative actions, as well as three civil actions for breach of contract, with potential material adverse effects if unfavorable outcomes occur.
• The company operates in a highly regulated, very competitive, and rapidly changing environment, with new risks emerging frequently that could affect actual results.

Future Outlook

The company plans to submit an enhanced version of its Co-Dx PCR COVID-19 test for 510(k) OTC clearance after collecting clinical evaluation data. This new submission will incorporate recent Co-Dx PCR platform developments to create greater operational and manufacturing efficiencies. The company anticipates continued operating losses and cash usage in the near term and expects to fund capital requirements through equity financing, additional grant funding, and operational efficiencies. There is no assurance that the Co-Dx PCR platform will receive regulatory approvals or be successfully commercialized.

Management Comments

• Management believes the proprietary and patented molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research.
• Management believes the company will be able to accomplish innovation faster and more economically than some competitors, allowing for significant margins while still positioning itself as a low-cost provider.
• The decision to withdraw the 510(k) submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability.
• The best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.
• The company expects to receive federal and state tax refunds related to prior years by the end of the year, resulting from new United States tax legislation signed into law on July 4, 2025.
• The company intends to use the net proceeds from recent equity financings for working capital and general corporate purposes.

Industry Context

The molecular diagnostics industry, particularly for infectious diseases, is highly competitive and rapidly evolving. While the company's proprietary PCR technology offers potential for low-cost, high-specificity testing, the significant decline in COVID-19 related revenue highlights the challenge of maintaining sales in a post-pandemic market. The focus on a portable, point-of-care platform aligns with a broader industry trend towards decentralized diagnostics, but regulatory hurdles and intense competition from established players remain significant challenges. The new joint venture in the MENA region indicates a strategy to expand into emerging markets, potentially diversifying revenue streams away from reliance on specific disease outbreaks.

Comparison to Industry Standards

• The company's rapid development and CE-marking for a COVID-19 test in early 2020 (just over 30 days) demonstrates a competitive advantage in agile test development compared to many industry peers who faced longer development cycles.
• The company's aim to be a 'low-cost provider of molecular diagnostics' while maintaining 'significant margins' through its proprietary platform positions it against larger diagnostic companies that may have higher overheads or royalty payments for licensed technologies.
• The withdrawal of the 510(k) application for the Co-Dx PCR COVID-19 Test due to shelf-life stability issues indicates a challenge in product robustness and regulatory compliance that could delay market entry compared to competitors who have successfully launched similar point-of-care devices.
• The 'going concern' warning is a significant deviation from the financial stability typically seen in more mature or profitable companies within the diagnostics industry, indicating a higher risk profile.

Corporate Governance

Legal Proceedings

• The company is a defendant in one class action claim and three derivative actions alleging false and misleading press releases to improperly benefit officers and directors, with plaintiffs demanding compensatory damages.
• The company is a party to three civil actions (two in the US, one in the UK) based on breach of contract claims.
• The company believes these lawsuits are without merit and is defending them vigorously, but is unable to estimate a range of loss. An unfavorable outcome could be material to results of operations.

Related Party Transactions

• The company has a services agreement with CoSara Diagnostics Pvt Ltd, its joint venture in India, for research and development consulting and support services. Expenses related to this agreement were $192,958 for Q3 2025 and $615,425 for the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent and planned equity offerings, coupled with a 'going concern' warning and substantial revenue decline, poses a high risk to shareholder value. The stock repurchase program is currently inactive.
• **Employees**: Continued R&D efforts and a new equity incentive plan could offer some stability and motivation, but the overall financial instability and cost-cutting measures may create uncertainty.
• **Customers**: The withdrawal of the FDA application for the Co-Dx PCR COVID-19 Test may delay access to a new point-of-care product, potentially impacting customer adoption and trust.
• **Creditors**: The 'going concern' warning and reliance on future financing increase the risk profile for creditors.
• **Joint Venture Partners**: The new JV with Arabian Eagle Manufacturing could open new market opportunities and shared development costs, potentially benefiting the partner.

Next Steps

• Collect clinical evaluation data to support the performance of the enhanced Co-Dx PCR COVID-19 test.
• Submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
• Incorporate more recent Co-Dx PCR platform developments into tests to create greater operational and manufacturing efficiencies.
• Seek additional equity financing, grant funding, and implement operational efficiencies to meet capital requirements.
• Continue defending against ongoing class action, derivative, and civil litigation.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a drastic decline in revenue, increased operational cash burn, and an explicit 'going concern' warning. While recent capital raises provide temporary liquidity, they are highly dilutive and do not address the fundamental lack of sustainable revenue generation. The withdrawal of a key product's FDA application further delays market entry and casts doubt on future growth prospects. Ongoing litigation adds to the uncertainty. Given these significant headwinds and the high risk of further dilution or even business failure, a 'strong sell' recommendation is warranted for investors.

Keywords

molecular diagnostics, PCR testing, Co-Dx PCR platform, COVID-19 test, SEC 10-Q, financial results, going concern, equity financing, biotechnology, medical devices, regulatory approval, FDA 510(k), infectious disease diagnostics, Co-Primers technology